Sitagliptin and Metformin Hydrochloride
- Product NDC
- 84677-053
- Requested package NDC
- 84677-053-18
- 11-digit product format
- 846770053
- Labeler code
- 84677
- Product ID
- 84677-053_58f0e7eb-dbcc-7207-e063-6294a90a40b1
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Sitagliptin and Metformin Hydrochloride
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Golden State Medical Supply, Inc.
- Application
- ANDA202426
- Marketing category
- ANDA
- Marketing start
- 2026-04-30
- Substance
- SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE
- Active strength
- 50; 1000 mg/1; mg/1
- Pharmacologic classes
- Biguanide [EPC], Biguanides [CS], Dipeptidyl Peptidase 4 Inhibitor [EPC], Dipeptidyl Peptidase 4 Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A202426-001 | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE | 500MG;EQ 50MG BASE | TABLET / ORAL | AB | 2026-04-30 | |
| A202426-002 | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE | 1GM;EQ 50MG BASE | TABLET / ORAL | AB | 2026-04-30 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A202426-001 | AB |
| A202426-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A202426-001 | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | 500MG;EQ 50MG BASE | TABLET / ORAL | AB | 2026-04-30 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A202426-002 | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | 1GM;EQ 50MG BASE | TABLET / ORAL | AB | 2026-04-30 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A202426-001 | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | 500MG;EQ 50MG BASE | TABLET / ORAL | AB | 2026-04-30 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A202426-002 | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | 1GM;EQ 50MG BASE | TABLET / ORAL | AB | 2026-04-30 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A202426-001 | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | 500MG;EQ 50MG BASE | TABLET / ORAL | AB | 2026-04-30 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A202426-002 | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | 1GM;EQ 50MG BASE | TABLET / ORAL | AB | 2026-04-30 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A202426-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A202426-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A202426-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A202426-002 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A202426-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A202426-002 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Sitagliptin and Metformin Hydrochloride
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| SITAGLIPTIN PHOSPHATE | 50 mg/1 |
| METFORMIN HYDROCHLORIDE | 1000 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 786Z46389E | Internal UNII lookup |
| TS63EW8X6F | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 58f0e875-5d9b-be0b-e063-6394a90a5345 | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sitagliptin and Metformin Hydrochloride | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | Golden State Medical Supply, Inc. | 58f0e875-5d9b-be0b-e063-6394a90a5345 | 2026-08-13 | Boxed warning, Warnings, Adverse reactions | 202426 ANDA202426 84677-053-18 84677-053 84677005318 |
| Sitagliptin and Metformin Hydrochloride | SITAGLIPTIN AND METFORMIN HYDROCHLORIDE | Apotex Corp. | 950613e2-e959-6b57-e172-251ddc53c64c | 2026-04-14 | Boxed warning, Warnings, Adverse reactions | 202426 ANDA202426 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 84677-053-18 | 84677005318 | 180 TABLET, FILM COATED in 1 BOTTLE (84677-053-18) | 2026-06-01 | No | No | Current |